Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Ovarian Carcinoma

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02487693

Enrollment

Registered

2015-07-01

Start date

2015-07-31

Completion date

2040-06-30

Last updated

2016-02-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian Carcinoma

Brief summary

The purpose of this study is to determine whether combining of radiofrequency ablation (RFA) and cytokine-induced killer cells (CIK) transfusion can prolong survival of patients with ovarian carcinoma.

Detailed description

The primary objective is to evaluate whether RFA followed by CIK transfusion can prolong survival of patients with ovarian carcinoma.

Interventions

PROCEDURERadiofrequency ablation

Radiofrequency ablation is performed percutaneously under CT/US guidance

BIOLOGICALCytokine-induced killer cells

The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Age

30 Years to 70 Years

Healthy volunteers

Inclusion criteria

1. patients diagnosed with FIGO stage II ovarian carcinoma; 2. cytoreductive surgery performed and 6 courses of platinum-based chemotherapy completed; 3. medical records maintain comprehensive data on treatment and follow-up; 4. no history of previous malignancies.

Exclusion criteria

1. neoadjuvant chemotherapy applied; 2. less than 6 courses of chemotherapy or more than 6 courses of chemotherapy completed; 3. medical records maintain incomplete data on treatment or follow-up; 4. history of previous malignancy.

Design outcomes

Primary

Measure	Time frame	Description
Recurrence-free survival	1 year	Recurrence-free survival (RFS) was defined as the time from the date of RFA to the date of recurrence or the date of the last follow-up.

Secondary

Measure	Time frame	Description
Adverse events	4 weeks	Adverse events related to RFA and CIK treatments.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026